Abstract
Background: In our study, we determined the changes in microalbuminuria and gfr (glomerular filtration rate) values, which are important for diabetic nephropathy, within 1 year after starting treatment in our patients taking DPP-4 inhibitor (linagliptin), GLP-1 analog (exenatide) and SGLT-2 inhibitor (empagliflozin).
 
 Material and Methods: We evaluated the urea, creatinine, gfr and microalbuminuria levels of our patients who were treated with linagliptin, exenatide and empagliflozin on their 0th, 6th and 12th month visits. We included patients who were followed up for nephropathy for at least 1 year after starting treatment in each drug group.
 
 Results: When the 0th and 12th month GFR values of our 98 patients who were prescribed linagliptin were compared, an increase of 4.57% was detected (p0.05). While no statistically significant difference was found in the 0th and 12th month GFR follow-ups of our 97 patients using exenatide (p>0.05); in this group, it was determined that the microalbuminuria decreased significantly in 12 months in 33 of our patients who could be followed up in terms of microalbuminuria (p0.05); however, it was determined that microalbuminuria decreased significantly at the end of 1 year in our 79 patients who could be followed up for microalbuminuria in this group (p
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call